Human Mass Balance and Metabolite Profiling of [(14)C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer

Pamiparib, a selective poly (ADP‐ribose) polymerase 1/2 inhibitor, demonstrated tolerability and antitumor activity in patients with solid tumors at 60 mg orally twice daily. This phase 1 open‐label study (NCT03991494; BGB‐290‐106) investigated the absorption, metabolism, and excretion (AME) of 60 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Song, Palmer, Daniel, Fitzgerald, Richard, Andreu‐Vieyra, Claudia, Zhang, Heather, Tang, Zhiyu, Su, Dan, Sahasranaman, Srikumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453745/
https://www.ncbi.nlm.nih.gov/pubmed/33876576
http://dx.doi.org/10.1002/cpdd.943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453745/
https://www.ncbi.nlm.nih.gov/pubmed/33876576
http://dx.doi.org/10.1002/cpdd.943

Ejemplares similares